Diagnostics for Lung Infections
Pearl Diagnostics is a Johns Hopkins University spin-off developing in vitro diagnostic assays that detect circulating microbial extracellular vesicles in urine to identify lung infections early and non-invasively. The company received FDA 510(k) clearance for its MycoMEIA Aspergillus Assay in August 2025 and has received investment from CARB-X, the Cystic Fibrosis Foundation, and Johns Hopkins Technology Ventures.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJul 2025
Feb 2025
Jun 2022
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
